Result

Ambalal Sarabhai Enterprises' board has approved the financial results for the quarter ended June 30, 2025. The company reported a consolidated net profit of Rs 8.22 Cr on revenue from operations of Rs 40.34 Cr, with consolidated EPS at Rs 1.07. Additionally, the board has constituted a Pharma Committee of Directors.

This committee, comprising Mr. Kartikeya V. Sarabhai, Mr. Mohal K. Sarabhai, and Mr. Govindprasad Namdeo, will strategically review, oversee compliance, and monitor the business performance of the pharma segment.

This move signals a focused approach on the pharmaceutical operations.